Ronald K. Yamamoto

Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom.

Halscion, Inc. developed technologies and biomaterial to treat dermatological conditions. It offered a device for the reduction in the appearance of scars resulting from acute surgical wounds. The company was founded by Charles E. Larsen, Thomas D. Weldon, and Gerard van Hamel Platerink in 2005 and was headquartered in Suwanee, GA.

POINT Biomedical Corp. develops biomedical-imaging products. It manufactures products for diagnostic, molecular imaging, and drug delivery applications based on biSphere technology. The company was founded in 1996 and is headquartered in San Carlos, CA.

iScience Interventional Corp. discovers and develops microcatheter and imaging technologies that enable ophthalmologists to deliver site-specific ocular therapies. It encompasses microcatheter-based therapies designed to access anatomical structures within the eye to aspirate ocular fluids or deliver sterile ophthalmic solutions to the eye. The firm addresses the previously unmet need for treatment of sight-threatening diseases with the innovative, minimally invasive iCath™ procedures. The company was founded by Michael F. Nash and Stan Conston in 1999 and is headquartered in Menlo Park, CA.